Robert Wieder

Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.

Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.

All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells.

Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow.

Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells.

Insurgent micrometastases: sleeper cells and harboring the enemy.

Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells.

TUNEL assay as a measure of chemotherapy-induced apoptosis.

Microfluidic techniques for single-cell protein expression analysis.

Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium.

Influence of prescription benefits on reported pain in cancer patients.

CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.

Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy.

A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.

Determination of single cell surface protein expression using a tagless microfluidic method.

Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling.

Establishing a minority-based community clinical oncology program: the University of Medicine and Dentistry of New Jersey, New Jersey Medical School-university Hospital Cancer Center experience.

Prescription coverage in indigent patients affects the use of long-acting opioids in the management of cancer pain.